Postprocessing of MRIs Using FreeSurfer in Epilepsy Surgery Patients Provides an Excellent Imaging Marker of Hippocampal Sclerosis but Fails to Separate Subtypes

Kloster, Ane G.; Opheim, Giske; Alfstad, Kristin; Larsen, Karen B.; Niehusmann, Pitt; Holm, Emil; Fink-Jensen, Philip; Lund, Eva Løbner; Jespersen, Bo; Ivanovic, Jugoslav; Rubboli, Guido; Madsen, Camilla G.; Marthinsen, Pål B.; Ganz, Melanie; Lossius, Morten; Pinborg, Lars H.

Published in:
Acta Neurologica Scandinavica

DOI:
10.1155/2023/2366355

Publication date:
2023

Document version
Publisher's PDF, also known as Version of record

Document license:
CC BY

Citation for published version (APA):
Research Article

Postprocessing of MRIs Using FreeSurfer in Epilepsy Surgery Patients Provides an Excellent Imaging Marker of Hippocampal Sclerosis but Fails to Separate Subtypes

Ane G. Kloster,1 Giske Opheim,1 Kristin Å. Alfstad,2 Karen B. Larsen,3,4 Pitt Niehusmann,5 Emil Holm,1 Philip Fink-Jensen,1 Eva Lobner Lund,3,4 Bo Jespersen,6 Jugoslav Ivanovic,7 Guido Rubboli,3,8 Camilla G. Madsen,9 Pål B. Marthinsen,10 Melanie Ganz,1,11 Morten Lossius,2,12 and Lars H. Pinborg1,3,13

1Neurobiology Research Unit, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark
2National Centre for Epilepsy, Oslo University Hospital, Norway
3Faculty of Health and Medical Sciences, University of Copenhagen, Denmark
4Department of Pathology, Copenhagen University Hospital-Rigshospitalet, Denmark
5Department of Pathology, Oslo University Hospital-Rikshospitalet, Norway
6Department of Neurosurgery, Copenhagen University Hospital-Rigshospitalet, Denmark
7Department of Neurosurgery, Oslo University Hospital-Rikshospitalet, Norway
8Danish Epilepsy Centre, Dianalund, Denmark
9Functional and Diagnostic Imaging Unit, Department of Radiology, Copenhagen University Hospital - Hvidovre, Denmark
10Department of Radiology, Oslo University Hospital-Rikshospitalet, Norway
11Department of Computer Science, University of Copenhagen, Denmark
12Institute of Clinical Medicine, University of Oslo, Norway
13Epilepsy Clinic, Department of Neurology, Copenhagen University Hospital-Rigshospitalet, Denmark

Correspondence should be addressed to Lars H. Pinborg; lars.pinborg@nru.dk

Received 2 September 2022; Revised 29 January 2023; Accepted 10 April 2023; Published 24 May 2023

Academic Editor: Dominic B. Fee

Copyright © 2023 Ane G. Kloster et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. Histopathological examinations will diminish as minimally invasive epilepsy surgery increasingly replaces open surgery. The objective of this study was to test if visual and computer-aided quantitative analyses of presurgical high-quality 3 Tesla MRIs complying with the International League Against Epilepsy (ILAE) Neuroimaging Task Force recommendations can inform on histopathological diagnosis. Methods. Ninety-two patients from Copenhagen and Oslo University Hospitals fulfilled patient-, imaging-, and histopathological inclusion criteria: 69 patients were diagnosed with hippocampal sclerosis (HS) ILAE type 1 or 2, and 23 patients had normal appearing hippocampi or other histopathology than HS (no-HS). MRIs from 52 healthy controls (HC) were included. Image processing was performed in FreeSurfer v.6.0 with the built-in cross-sectional hippocampal subfield segmentation tool and multimodal MRI input. Volume outputs were used to calculate volume asymmetry ratios (VARs) for whole hippocampus (WH) and subfields. Results. HS patients had significantly larger WH VARs compared to no-HS patients and HC, with a sensitivity = 0.93 and specificity = 1.0 for histopathological HS diagnosis. Visual MRI assessment yielded a sensitivity = 0.90 and specificity = 0.96 for histopathological HS diagnosis. CA1 and CA4 VARs and the number of seizure-free patients were not significantly different in HS ILAE type 1 compared to type 2 patients. Significance. FreeSurfer analyses of presurgical MRIs are excellent at separating patients histopathologically diagnosed with HS from patients with other pathology or normal appearing hippocampi. Using the FreeSurfer hippocampal subfield segmentation tool did not allow for separating HS ILAE subtypes.
1. Introduction

In 2019, the International League Against Epilepsy (ILAE) Neuroimaging Task Force recommended the use of the Harmonized Neuroimaging of Epilepsy Structural Sequences Magnetic Resonance Imaging (HARNESS-MRI) protocol with isotropic, millimetric 3D T1-weighted (T1w) and fluid-attenuated inversion recovery (FLAIR) images and high-resolution 2D submillimetric T2-weighted (T2w) images for best-practice neuroimaging of epilepsy patients [1]. The Task Force endorsed the use of computer-aided image postprocessing methods to provide an objective account of an individual’s brain anatomy and pathology [1].

Hippocampal sclerosis (HS) is the archetypal abnormality found in temporal lobe epilepsy (TLE) patients [2]. HS patients are frequently drug-resistant [3–5] and may be eligible for surgical intervention with seizure freedom rates ranging between 53 and 84% one year after surgery [6, 7]. HS is histopathologically characterized by segmental loss of pyramidal neuronal cells and increased gliosis (i.e., sclerosis) of the hippocampus. In 2013, the ILAE Commission on Diagnostic Methods [8] introduced a new semiquantitative classification system for HS, depending on the specific pattern of neuronal cell loss within the four different subfields of the hippocampal cornu ammonis (CA) [8]. HS ILAE type 1 is characterized by severe neuronal cell loss in both CA1 and CA4 subfields, while HS ILAE type 2 and type 3 predominantly portray neuronal loss in CA1 or CA4 subfield, respectively. The aim of the classification was to establish a single and reproducible system across centers that differentiates histopathological subgroups and their relation to postsurgical outcomes and comorbidities [8–11]. HS ILAE type 1 has been found to associate with better postsurgical seizure outcomes [8, 9] and memory performance [10, 11] than HS ILAE types 2 and 3. But, the clinical use of HS ILAE classification as a biomarker of postsurgical seizure outcome is limited by its post hoc histopathological confirmation.

HS is diagnosed with high accuracy in MRI by reduced hippocampal volume, obscuration of normal internal architecture, and increased T2w or FLAIR signal intensity on hippocampal volume, obscuration of normal internal architecture, and increased T2w or FLAIR signal intensity on hippocampal subfields and hippocampal neuronal densities in 24 patients.

In this study, we analyzed the findings of 92 surgically treated and histopathologically diagnosed TLE patients from Denmark and Norway and compared them to 52 healthy controls. We used high-quality 3 T T1w and T2w MRIs similar to the proposed HARNESS-MRI protocol, the updated hippocampal subfield segmentation tool [22] in FreeSurfer version 6.0 [21], and a simple volume asymmetry ratio (VAR) to test if the presurgical MRI scan is an accurate biomarker for separating HS from other pathologies or normal appearing hippocampal tissue, (ii) for HS ILAE classification, and (iii) for predicting seizure outcome one year after surgery.

2. Methods

2.1. Patients. In this retrospective two-center study, we identified 354 consecutive surgically treated TLE patients at Copenhagen University Hospital-Rigshospitalet in Denmark (n = 255) operated between 2009 and 2020 and Oslo University Hospital Rikshospitalet in Norway (n = 99) operated between 2012 and 2018. These epilepsy surgery centers conduct all epilepsy surgery procedures in the respective countries and thus represent whole population cohorts. The study was approved by the Danish Protection Agency and the Danish Patient Safety Authority (case numbers 3-3013-1030/1 and 3-3013-3074/1), the Norwegian Regional Committees for Medical and Health Research Ethics (case number 64559), and the Data Protection Office of Oslo University Hospital (case number 20/01450). Parts of the Danish patient material was included in the PhD thesis by coauthor Opheim [26].

In the Norwegian cohort, one patient declined to participate in the study. Preoperative MRIs could not be retrieved in the picture archiving and communication system (PACS) for 34 patients from the Danish cohort operated between 2009 and 2013. To ensure the quality and consistency in the dataset, all patients’ MRI sequences were carefully evaluated under the criteria listed in Table 1. A full overview of the patient inclusion and exclusion process is shown in Figure 1, resulting in 92 included TLE patients. They underwent either anteromedial temporal lobectomy (n = 91) or selective amygdalohippocampectomy (n = 1) and were divided into two groups according to histopathological diagnosis: HS (n = 69) or no-HS (n = 23) (Figure 1). The HS patients were subdivided according to the ILAE classification for hippocampal sclerosis [8]. No patients were classified as HS ILAE type 3, resulting in the following patient groups: HS ILAE type 1 (n = 64), HS ILAE type 2 (n = 5), and no-HS (n = 23). The no-HS patient group is a histopathologically heterogeneous group. It consists of patients without any histopathological signs of HS and includes TLE patients with tumors or focal cortical dysplasia (FCD) within or outside [20, 23, 24] or 3 [23, 24]. The number of patients was small (n ≤ 28), and high-resolution multimodal input for optimal performance of hippocampal segmentation was not used [19, 22]. Mizutani et al. [25] applied multimodal input and the Automatic Segmentation of Hippocampal Subfield tool but found no correlation between hippocampal subfield volumes and subfield neuronal densities in 24 patients.

The development of neuronal cell loss within the four di...
The classiﬁcation marker). The reagents used for immunostaining came from eosin or used for immunohistochemistry (NeuN, neuronal signal as generated with a 3,3′-diaminobenzidine-tetrahydrochloride (DAB chromogen) for 10 minutes. Hematoxylin was used for counterstaining. To ensure correct HS ILAE classiﬁcation across countries, consensus understanding of the classiﬁcation was discussed beforehand and veriﬁed by direct contact with the ﬁrst author of the HS ILAE consensus article Dr. I. Blümcke [8]. All specimens were examined by neuropathologists specialized in evaluating epilepsy surgery tissue, blinded to the volumetry results. All HS specimens were reexamined to ensure correct ILAE classiﬁcation. Specimens with uncertain ﬁndings were discussed among colleagues, and if consensus on classiﬁcation was not possible, the cases were labeled “no HS subclassiﬁcation” and excluded from the study (13 of 82 HS patients, 16%, Figure 1).

2.4. MRI Scan Protocol. Danish patients and healthy controls were imaged at Copenhagen University Hospital, Hvidovre, using Siemens Healthcare Magnetom Verio (patients, n = 73) and Magnetom Trio (healthy controls, n = 52) 3 T MRI systems with 32- and eight-channel head coils, respectively. Norwegian patients were imaged at Oslo University Hospital, Rikshospitalet, using Siemens Healthcare Magnetom Skyra (n = 17) or Philips Healthcare Achieva (n = 2) 3 T MRI systems with a 32-channel or eight-channel head coil, respectively. Speciﬁcations of the applied MRI sequences are listed in Table 1. More details on the MRI acquisition parameters are available in the supplementary information (available here).

2.5. Neuroradiological Visual Assessment. All patients’ MRIs were routinely visually examined and diagnosed upon acquisition and then reassessed by neuroradiologists trained at detecting epileptogenic lesions as part of the presurgical evaluation of epilepsy patients. The neuroradiologists were blinded to both histopathology and volumetric analyses.

2.6. Postsurgical Seizure Outcome. The seizure outcomes were assessed for all patients one year following surgery. The patients were classiﬁed according to the ILAE outcome score [28] into seizure-free (ILAE class 1) and non-seizure-free (ILAE classes 2–6).

2.7. Data Analysis. Image processing was performed in FreeSurfer version 6.0 [21], with the built-in cross-sectional hippocampal subﬁeld segmentation tool [22]. All hippocampal segmentations were performed with the multimodal option of adding T2w images as overlays to the T1w images to increase boundary tracing accuracy in the outer hippocampi as well as in the subﬁelds. The hippocampal subﬁeld segmentation outputs from both Copenhagen and Oslo were visually quality assessed by the same experienced observer. Left and right hippocampal volumes (whole hippocampus (WH), CA1, and CA4) were exported for statistical analysis.

2.8. Statistical Analysis. In MATLAB (R2021a), VARs were calculated for each hippocampal region (WH, CA1, and CA4) were exported for statistical analysis.

### Table 1: Patient MRI inclusion and exclusion criteria. Details on the individual MRI acquisition parameters are available in supplementary information.

<table>
<thead>
<tr>
<th>MRI inclusion and exclusion criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Inclusion criteria</strong></td>
</tr>
<tr>
<td>(i) Presurgical 3 T MRIs from Copenhagen University Hospital Hvidovre or Oslo University Hospital Rikshospitalet including the following sequences:</td>
</tr>
<tr>
<td>(a) 3D MPRAGE T1w images with isotropic millimetric voxel resolution</td>
</tr>
<tr>
<td>(b) 2D TSE T2w coronal images with high in-plane submillimetric voxel resolution</td>
</tr>
<tr>
<td><strong>Exclusion criteria</strong></td>
</tr>
<tr>
<td>(i) MRI abnormalities hampering successful processing in FreeSurfer, entailing:</td>
</tr>
<tr>
<td>(a) Structural nonepileptogenic lesions (i.e., not presumed to be part of seizure generation or propagation)</td>
</tr>
<tr>
<td>(b) Previous brain surgery</td>
</tr>
<tr>
<td>(c) Marked movement artefacts</td>
</tr>
</tbody>
</table>

MRI = magnetic resonance imaging; 3 T = 3 Tesla; MPRAGE = magnetization-prepared rapid acquisition gradient echo; T1w = T1-weighted; FSE = fast spin-echo; T2w = T2-weighted.
characteristic (ROC) curves using the built-in perfcurve function. Statistical testing at group level was performed in R (R Core Team 2021) using the two-tailed Wilcoxon Mann–Whitney (WMW) rank-sum test from the asht package. p values were calculated by asymptotic method or by exact method with complete enumeration or the Monte Carlo implementation in comparisons where the small HS ILAE type 2 patient group (n = 5) was included. All p values were corrected for multiple comparison ad modum Bonferroni \(P_{\text{corrected}} = P_{\text{uncorrected}} \times 8 \text{comparisons} \times 3 \text{regions})\). From the asht package, effect sizes (WMW estimates) were calculated for each comparison, expressing the probability that the VAR of a randomly selected subject from one group is larger than the VAR of a randomly selected subject from another group. Student’s t-test and chi-square or Fischer’s exact test were used for testing demographic and seizure outcome group differences for continuous and categorical variables, respectively.

3. Results

In Figure 2, VARs of patients and healthy controls are graphically depicted as a violin plot. It demonstrates the significantly larger VAR values found throughout all regions in HS patients compared to the no-HS patients and healthy controls (Table 2). Figure 3(a) shows a bootstrapped \((n = 1000)\) ROC curve for detection of HS based on WH and CA1 VARs in the HS patient group versus the no-HS patient group. ROC curve analysis yielded an AUC\_WH of 0.98 with a sensitivity of 0.93 and specificity of 1.0 at the optimal cutoff for diagnosis (VAR\_WH \(\geq 0.06\)). AUC\_CA1 was also 0.98, with sensitivity of 0.97 and specificity of 0.91 at the optimal cutoff for diagnosis (VAR\_CA1 \(\geq 0.04\)).

Figure 3(b) shows the contingency table for HS diagnosis by neuroradiological visual assessment, with a sensitivity of 0.90 and specificity of 0.96. One of 23 no-HS patients (4%) was misdiagnosed with HS by the neuroradiologist but correctly diagnosed by the computer-aided WH VAR approach. Seven of 69 HS patients (10%) were not diagnosed with HS by neuroradiological visual examination, whereas the computer-aided VAR approach correctly identified the patients as having HS in five of seven cases. In three of these seven cases, the neuroradiologists described possible but not decisive signs of HS. Reversely, the computer-aided VAR approach did not misdiagnose any no-HS patients as having HS but failed to diagnose HS in five of 69 HS patients (7%). Three of these five were correctly diagnosed with HS by visual examination (one solely on increased signal intensity). The combined performance of HS diagnosis by the computer-aided VAR approach and visual assessment yielded a sensitivity and specificity of 0.97 and 1.0, respectively.

Statistical testing of groups with the WMW rank-sum test showed significantly increased VAR in WH, CA1, and CA4 for both HS ILAE type 1 and type 2 compared to healthy controls and the no-HS patient group, with large effect size measures (\(\geq 0.96\)) (see p values and effect sizes in Table 2). The WMW effect size estimates for WH and CA1 VAR differences between the HS and no-HS patient groups were equal to the AUCs of the ROC curve (0.98). There were no significant VAR differences in WH, CA1, and CA4 when comparing HS ILAE type 1 with type 2, effect sizes 0.34–0.57. There were no significant VAR differences between the no-HS patient group and healthy controls, effect sizes 0.36–0.41.
In the HS patient group, 43 of 69 patients (62%) were seizure-free one year following surgery, compared to 15 of 23 (65%) in the no-HS patient group, with no significant difference between the two groups ($x^2(1, n = 92) = 0.062, p = 0.80$). There was no significant difference in the number of seizure-free HS ILAE type 1 (39 of 64, 61%) and type 2 (4 of 5, 80%) patients ($p = 0.64, \text{Fisher’s exact test}$). We found no difference in WH or subfield VARs of seizure-free HS patients (43 of 69, 62%) versus non-seizure-free HS patients (26 of 69, 38%) ($p \geq 0.65, \text{WMW rank-sum test}$). ROC curve of WH VAR in seizure-free versus non-seizure-free HS patients showed no differentiating ability of the WH VAR in predicting seizure outcome, with an AUC of 0.53.

Demographic data of patients and controls are presented in Table 3. There was a significant difference in mean age between patients and healthy controls ($p = 0.00049, \text{Student’s t-test}$). Age was not correlated to WH VAR using linear regression ($R^2 = 0.000060 - 0.021, p = 0.17 - 0.96$). There was no significant difference in gender between patients and controls ($x^2(1, n = 144) = 0.22, p = 0.64$). Years with epilepsy ($p = 0.00008, \text{Student’s t-test}$) and years with drug resistance ($p = 0.02, \text{Student’s t-test}$) were both significantly longer in HS patients compared to the no-HS patients. In HS ILAE type 1 and type 2 patients, there was no significant difference in years with epilepsy ($p = 0.11, \text{Student’s t-test}$) or years with drug resistance ($p = 0.74, \text{Student’s t-test}$).
AUCWH = 0.98  
SensitivityWH = 0.93  
SpecificityWH = 1.0  
AUCCA1 = 0.98  
SensitivityCA1 = 0.97  
SpecificityCA1 = 0.91

Figure 3: HS diagnosis by computer-aided method (a) and expert visual assessment (b). (a) The bootstrapped (n = 1000) receiver operator characteristic (ROC) curve for detection of HS based on WH and CA1 volume asymmetry ratios (VARs) in the HS patient group versus the no-HS patient group. For each data point, the brackets represent the bootstrap-generated confidence interval for the curve. The text box lists the area under the curve (AUC) values and the sensitivity, specificity, and VAR values at the optimal threshold of the curve (blue and red circles). (b) The contingency table for HS diagnosis by visual examination performed by neuroradiologists specialized in epilepsy diagnostics. HS = hippocampal sclerosis; WH = whole hippocampus; TP = true positives; FP = false positives; TN = true negatives; FN = false negatives.

Table 3: Demographic characteristics of patients and controls.

<table>
<thead>
<tr>
<th></th>
<th>Healthy controls (N = 52)</th>
<th>HS ILAE 1 (N = 64)</th>
<th>HS ILAE 2 (N = 5)</th>
<th>No-HS (N = 23)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>25 (48%)</td>
<td>36 (56%)</td>
<td>4 (80%)</td>
<td>8 (35%)</td>
</tr>
<tr>
<td>Male</td>
<td>27 (52%)</td>
<td>28 (44%)</td>
<td>1 (20%)</td>
<td>15 (65%)</td>
</tr>
<tr>
<td>Age (years)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>48 (±21)</td>
<td>36 (±17)</td>
<td>43 (±12)</td>
<td>35 (±13)</td>
</tr>
<tr>
<td>Years with epilepsy</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>21 (±16)</td>
<td>36 (±16)</td>
<td>11 (±8.2)</td>
<td></td>
</tr>
<tr>
<td>Years with drug resistance</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>17 (±14)</td>
<td>19 (±16)</td>
<td>11 (±8.4)</td>
<td></td>
</tr>
<tr>
<td>Laterality</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Left</td>
<td>26 (50%)</td>
<td>37 (58%)</td>
<td>1 (20%)</td>
<td>16 (70%)</td>
</tr>
<tr>
<td>Right</td>
<td>26 (50%)</td>
<td>27 (42%)</td>
<td>4 (80%)</td>
<td>7 (30%)</td>
</tr>
<tr>
<td>Outcome</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-seizure-free</td>
<td>25 (39%)</td>
<td>1 (20%)</td>
<td>8 (35%)</td>
<td></td>
</tr>
<tr>
<td>Seizure-free</td>
<td>39 (61%)</td>
<td>4 (80%)</td>
<td>15 (65%)</td>
<td></td>
</tr>
</tbody>
</table>

*Years with epilepsy*: years from diagnosis of epilepsy to surgery. *Duration drug-resistant*: years of drug-resistant epilepsy (i.e., failure of adequate trials of two appropriately chosen and used antiepileptic drug schedules [45]). *Laterality*: side of operation (patients) or randomized (HC). *Outcome*: seizure outcome one year after surgery according to the ILAE outcome score [28], where seizure-free patients have a score of 1 (completely seizure-free) and the non-seizure-free patients have any form of seizures with scores 2-5 (from auras only to an increase in baseline seizure days). Categorical values are presented with frequencies and percentages and continuous values with means and standard deviations (SD).
4. Discussions

4.1. Presurgical MRI as a Biomarker for Diagnosing HS. In this study, we demonstrate that combining a presurgical high-quality T1w and T2w 3T MRI protocol, the updated hippocampal subfield segmentation tool implemented in FreeSurfer v. 6.0, and a simple VAR is an excellent biomarker for separating patients histopathologically diagnosed with HS from patients with other pathology or normal appearing hippocampi.

The violin plot in Figure 2 clearly shows the VAR differences between TLE patients with and without HS. The ability of both WH and CA1 VAR to diagnose HS among TLE patients is demonstrated in the ROC plot in Figure 3(a) with excellent AUC values of 0.98 and remarkably high sensitivities and specificities > 0.9 at VAR thresholds of 0.06 and 0.04, respectively. Reduced WH volume is a recognized MRI surrogate marker for HS [1, 13–18]. Even though CA1 makes up almost 50% of the total hippocampal volume [20] and is specifically affected in both HS ILAE type 1 and 2 [8], CA1 VAR did not diagnose HS with greater specificity compared to the WH VAR. This may be due to a ceiling effect related to the excellent AUC values of both approaches. Compared to previous studies, we find the highest accuracy for a computer-aided HS diagnosis [15, 16, 30]. Our study is unique in combining very strict patient and imaging criteria for inclusion of patients, a large sample of epilepsy surgery patients, the use of the newest FreeSurfer segmentation tool and comparing operated patients with a histopathologically verified HS diagnosis to patients with a no-HS diagnosis.

We demonstrated that the ability to separate HS patients from no-HS patients by quantitative hippocampal assessment using FreeSurfer is very similar to visual MRI assessment by experienced neuroradiologists in the epilepsy surgery teams (Figure 3) and that combining the visual and computer-aided assessment further improved the sensitivity and specificity to 0.97 and 1.0, respectively. This observation is of clinical significance particularly looking into a future where minimal invasive surgery techniques [31–33] will preclude histopathological examination and presurgical MRI will be increasingly important as a biomarker for histopathology. But the patients to benefit the most from introducing the HARNESS-MRI protocol and computer-aided image postprocessing methods are most likely patients newly diagnosed with epilepsy, where MRI lesions may be subtle and easily overlooked [1, 18, 30]. The early identification of HS is of importance for clinicians to inform patients on best possible epilepsy treatment and mitigate the potential consequences of drug resistance [4, 34] and thence cognitive decline, psychiatric disease, and reduced quality of life [5, 35].

4.2. Presurgical MRI as a Biomarker for HS ILAE Classification. Contrary to what we expected, we found no significant difference in CA4 VARs in patients histopathologically classified as HS ILAE type 1 compared to HS ILAE type 2 ($p = 1.0$, Table 2), and the CA4 VARs were significantly larger in both HS ILAE type 1 and 2 patients compared to no-HS patients and healthy controls ($p < 0.005$) (Table 2 and Figure 2). The statistical power of our analysis is challenged by the fact that only five patients were histopathologically classified with HS ILAE type 2, but we expect that a computer-aided VAR approach for differentiating ILAE subtypes must provide robust results in individual patients to be feasible in a clinical setting.

Peixoto-Santos et al. [20] is the only other study to test computer-aided subfield volumes of different histopathological HS ILAE types against each other, reporting no subfield VAR differences between HS ILAE types 1 ($n = 22$) and 2 ($n = 6$). Notably, they performed subfield volumetry by manual segmentation in the same HS ILAE type 2 patients, finding intact CA4 subfield volumes and reduced subfield volume only in CA1, in accordance with the histopathological neuronal cell loss. Their findings are corroborated by previous studies showing good correlation between manual subfield volumetry and ILAE classification [1, 8, 14, 20]. The discrepancy between manual and computer-aided segmentations implies that the FreeSurfer hippocampal subfield segmentation tool fails in epilepsy patients with HS. The segmentation algorithm is based upon a probability atlas derived from manual delineations of ex vivo and in vivo MRIs from ten healthy subjects, four subjects with Alzheimer’s disease, and one subject with mild cognitive impairment [22]. We suspect that the FreeSurfer probability atlas is too rigid when setting priors for the hippocampal subfields in epilepsy patients and in particular in HS ILAE type 2 patients, where the subfield morphology is more unevenly distorted across the hippocampal subfields compared to healthy controls and patients with Alzheimer’s disease [36].

4.3. Presurgical MRI as a Biomarker for Postsurgical Seizure Outcomes. In contrast to most published studies [5, 7, 37], we did not find a significant difference in seizure outcome one year after surgery in patients histopathologically diagnosed with HS compared to no-HS patients. The presurgical evaluation program varies among different epilepsy surgery centers, which will impact seizure outcome. In our centers, we acquire presurgical fluorodeoxyglucose positron emission tomography (FDG-PET) scans and intracranial EEG registration (ICR) in a relatively high proportion of MRI-negative patients or patients with discordant MRIs, seizure semiology, and EEG findings. Both FDG-PET [5, 37] and ICR [38, 39] are predictors of a positive surgical outcome. In our cohort, FDG-PET scans were acquired in 20 of 23 patients (87%) in the no-HS group who did not have an apparent lesion visible on MRI. Functional deficit zones concordant with the surgical resection site were present in 18 of these 20 patients. In 13/23 no-HS patients (57%), the epileptogenic zone was identified after ICR. In comparison, FDG-PET scans were acquired in 21/69 HS patients (45%) and ICR performed in 9/69 HS patients (13%). The good surgical outcomes of the no-HS patient group are most likely a result of the extensive presurgical evaluation program.

It is a dogma in epilepsy surgery that HS ILAE type is important for seizure freedom after hippocampectomy. In our study, no difference in seizure outcome was found between HS ILAE type 1 and 2 patients. However, the hypothesis that HS ILAE subtypes are predictive of seizure
freedom is supported by a limited number of studies: Blümcke et al. [40] found two of seven (29%) patients with neuronal loss restricted to the hilar region of hippocampus (= HS ILAE type 3) to achieve postsurgical seizure freedom, compared with 18 of 25 (72%) and six of nine (67%) of patients with neuronal loss similar to HS ILAE type 1 and type 2, respectively. In the studies by Thom et al. [41] and Stefan et al. [42], the patients with CA1 predominant HS (= HS ILAE type 2) had a poor seizure outcome. Calderon-Garcidueñas et al. [43] showed a significant reduction in long-term seizure freedom (Engel class 1a) only in a subgroup of HS ILAE type 1 patients with hypertrophic CA4 neurons. Thus, clinical significance of the failure of FreeSurfer to separate HS ILAE type 1 from HS ILAE type 2 appears limited. Nonetheless, future studies should include long-term postsurgical outcome assessments, as patients may have seizure relapse after the one-year follow-up period applied in our study.

5. Methodological Considerations

In this study, we provide strong clinical validation for using the HARNESS-MRI protocol, computer-aided postprocessing in FreeSurfer, and a simple volume asymmetry ratio to separate patients diagnosed with HS from patients with other or normal pathology. However, it is important to emphasize that not all patients with a potential epileptogenic zone involving the hippocampus will benefit from computer-aided postprocessing of presurgical MRIs. According to Figure 1, 32/353 patients were excluded due to previous brain surgery, which hampers proper brain segmentation in FreeSurfer. FreeSurfer segmentation errors led to exclusion of 20/218 patients. Software for segmentation and methodology for correction of minor movement artefacts are likely to improve in the years to come, but for now, exclusion of 10% of the cohort is a large number. Five of 137 patients were excluded due to bilateral hippocampal pathology. This is probably an underestimation of the proportion of patients evaluated for epilepsy surgery with bilateral hippocampal pathology, since these patients are rarely offered epilepsy surgery. Using a volume asymmetry ratio as applied in our study precludes detection of subtle bilateral pathology, where the neuroradiological findings are scarce.

The right hippocampal volume has been demonstrated to be larger than the left hippocampal volume of healthy volunteers [44]. Although the difference in volume is small and large populations are needed to demonstrate a significant difference in volume with sufficient power, a subtle reduction in right hippocampal volume could in theory be outbalanced by an increase in hippocampal volume on the right side compared to the left side and influence our results. We found a significant difference in years of epilepsy and years of drug resistance between HS patients and no-HS patients, as well as a difference in mean age between the patients and the healthy control group of this study. Linear regression analysis found no correlation between age and VAR, and previous meta-analyses [44] on hippocampal asymmetry do not report changes in left-right asymmetry with increasing age. Finally, the results of this study are in-sample results, and validation in a new external dataset is warranted.

Data Availability

Given patients’ sensitive information and General Data Protection Regulations (GDPR), the data that support the findings of this study is not publicly available. However, access to data (in anonymized form) will be granted from the corresponding author upon request but may require the completion of a formal data sharing agreement, in compliance with GDPR and Norwegian and Danish legislation.

Conflicts of Interest

None of the authors have any conflict of interest to disclose.

Acknowledgments

The project was supported by the Independent Research Fund Denmark | Medical Sciences (FSS) (grant ID: 7016-00151B), the Research Council of Rigshospitalet (grant ID: R181-A8114), the Lundbeck Foundation BrainDrugs (grant ID: R279-2018-1145), and Lundbeck Foundation (grant ID: R187-2015-2150). We thank the Norwegian Epilepsy Surgery group at the National Centre for Epilepsy and Rikshospitalet at Oslo University Hospital and the Danish Epilepsy Surgery group at the Copenhagen University Hospital-Rigshospitalet, and the Epilepsy Hospital Filadelfia for providing patient data. We thank Dr. Brice Ozenne for his valuable assistance with statistical analysis and Dr. Rune Markhus for assisting with retrieval of MRI data at Oslo University Hospital.

Supplementary Materials

MRI acquisition parameters. (Supplementary Materials)

References


